Evidence map›Paper›PMID 37649486›Full record

ArticleFrontiers in immunology2023

Growth hormone-releasing hormone antagonist MIA-602 inhibits inflammation induced by SARS-CoV-2 spike protein and bacterial lipopolysaccharide synergism in macrophages and human peripheral blood mononuclear cells.

Giuseppina Granato, Iacopo Gesmundo, Francesca Pedrolli, Ramesh Kasarla, Laura Begani, Dana Banfi, Stefania Bruno, Tatiana Lopatina, Maria Felice Brizzi, Renzhi Cai and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Effects of GHRH and its analogues on the Vascular System.Reviews in endocrine & metabolic disorders · 2025
    Review
  5. Growth hormone - releasing hormone in the immune system.Reviews in endocrine & metabolic disorders · 2025
    Review
  6. Growth hormone-releasing hormone and cancer.Reviews in endocrine & metabolic disorders · 2025
    Review
  7. Growth hormone-releasing hormone receptor (GHRH-R) and its signaling.Reviews in endocrine & metabolic disorders · 2025
    Review
  8. GHRH in diabetes and metabolism.Reviews in endocrine & metabolic disorders · 2025
    Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Giuseppina GranatoDepartment of Medical Sciences, Division of Endocrinology, Diabetes and Metabolism, University of Turin, Turin, Italy.
Iacopo GesmundoDepartment of Medical Sciences, Division of Endocrinology, Diabetes and Metabolism, University of Turin, Turin, Italy.
Francesca PedrolliDepartment of Medical Sciences, Division of Endocrinology, Diabetes and Metabolism, University of Turin, Turin, Italy.
Ramesh KasarlaDepartment of Medical Sciences, Division of Endocrinology, Diabetes and Metabolism, University of Turin, Turin, Italy.
Laura BeganiDepartment of Medical Sciences, Division of Endocrinology, Diabetes and Metabolism, University of Turin, Turin, Italy.
Dana BanfiDepartment of Medical Sciences, Division of Endocrinology, Diabetes and Metabolism, University of Turin, Turin, Italy.
Stefania BrunoDepartment of Medical Sciences, University of Turin, Turin, Italy.
Tatiana LopatinaDepartment of Medical Sciences, University of Turin, Turin, Italy.
Maria Felice BrizziDepartment of Medical Sciences, University of Turin, Turin, Italy.
Renzhi CaiEndocrine, Polypeptide, and Cancer Institute, Veterans Affairs Medical Center, Miami, FL, United States.
Wei ShaEndocrine, Polypeptide, and Cancer Institute, Veterans Affairs Medical Center, Miami, FL, United States.
Ezio GhigoDepartment of Medical Sciences, Division of Endocrinology, Diabetes and Metabolism, University of Turin, Turin, Italy.
Andrew V SchallyEndocrine, Polypeptide, and Cancer Institute, Veterans Affairs Medical Center, Miami, FL, United States.
Riccarda GranataDepartment of Medical Sciences, Division of Endocrinology, Diabetes and Metabolism, University of Turin, Turin, Italy.
University of Turin · ITSouth Florida Veterans Affairs Foundation for Research and Education · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 is characterized by an excessive inflammatory response and macrophage hyperactivation, leading, in severe cases, to alveolar epithelial injury and acute respiratory distress syndrome. Recent studies have reported that SARS-CoV-2 spike (S) protein interacts with bacterial lipopolysaccharide (LPS) to boost inflammatory responses

Indexed as

COVID-19Spike Glycoprotein, CoronavirusEndothelial CellsGrowth Hormone-Releasing HormoneHumansInflammationLeukocytes, MononuclearLipopolysaccharidesSARS-CoV-2SermorelinTumor Necrosis Factor-alphaGHRH(1-29)NH2, (PhAc-Ada)(0)-Tyr(1), Arg(2), Fpa(5,6), Ala(8), Har(9), Tyr(Me)(10), His(11), Orn(12,) Abu(15), His(20), Orn(21), Nle(27), Arg(28), Har(29)-Growth Hormone-Releasing HormoneLipopolysaccharidesSermorelinSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Tumor Necrosis Factor-alphaGHRHGHRH antagonistinflammationmacrophagesperipheral blood mononuclear cells (PBMC)SARS-CoV-2 spike protein

Identifiers

PMID37649486
PMCPMC10462983
OpenAlexW4385876179

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.